Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Eli Lilly and Company

Capitalization 895B 768B 694B 665B 1,214B 82,164B 1,253B 8,178B 3,275B 39,391B 3,357B 3,286B 141,039B P/E ratio 2026 *
29.4x
P/E ratio 2027 * 24.9x
Enterprise value 910B 782B 706B 676B 1,235B 83,596B 1,274B 8,321B 3,332B 40,078B 3,416B 3,343B 143,496B EV / Sales 2026 *
11.1x
EV / Sales 2027 * 9.4x
Free-Float
99.81%
Yield 2026 *
0.66%
Yield 2027 * 0.74%
1 day-0.70%
1 week-0.63%
Current month-4.81%
1 month-2.31%
3 months+0.78%
6 months+32.70%
Current year-6.82%
1 week 965.6
Extreme 965.6
1,012
1 month 965.6
Extreme 965.6
1,067
Current year 965.6
Extreme 965.6
1,133.95
1 year 623.78
Extreme 623.78
1,133.95
3 years 317.24
Extreme 317.24
1,133.95
5 years 178.58
Extreme 178.5779
1,133.95
10 years 64.18
Extreme 64.18
1,133.95
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2017
Director of Finance/CFO 49 09/09/2024
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 65 01/01/2005
Director/Board Member 69 01/04/2009
Director/Board Member 54 12/12/2011
Change 5d. change 1-year change 3-years change Capi.($)
-0.70%-0.63%+20.68%+217.87% 895B
+0.46%-1.23%+45.32%+60.75% 587B
-0.19%-2.93%+4.78%+51.63% 401B
-1.61%-8.61%+10.59%+24.09% 345B
-0.57%-5.31%+26.33%+61.80% 300B
-0.94%-4.08%+26.06%+35.43% 306B
-0.02%-2.29%+22.95%+8.73% 289B
-0.41%-0.42%+14.68%+64.76% 202B
+1.32%+0.49%+26.75%+86.87% 184B
+0.53%+0.92%-53.31%-49.65% 171B
Average -0.23%-1.14%+14.48%+56.23% 368.14B
Weighted average by Cap. -0.34%-1.51%+19.56%+84.79%

Financials

2026 *2027 *
Net sales 82.11B 70.51B 63.74B 61.03B 111B 7,542B 115B 751B 301B 3,616B 308B 302B 12,946B 94.81B 81.41B 73.59B 70.46B 129B 8,708B 133B 867B 347B 4,175B 356B 348B 14,947B
Net income 30.39B 26.1B 23.59B 22.59B 41.25B 2,791B 42.55B 278B 111B 1,338B 114B 112B 4,792B 36.2B 31.09B 28.1B 26.9B 49.14B 3,325B 50.69B 331B 133B 1,594B 136B 133B 5,708B
Net Debt 15.59B 13.39B 12.1B 11.59B 21.16B 1,432B 21.83B 143B 57.06B 686B 58.5B 57.26B 2,458B -3.14B -2.7B -2.44B -2.33B -4.26B -288B -4.4B -28.7B -11.49B -138B -11.78B -11.53B -495B
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
10/03/26 1,001.35 $ -0.70% 1,663,668
09/03/26 1,008.39 $ +1.82% 2,802,169
06/03/26 990.33 $ +0.72% 2,627,805
05/03/26 983.26 $ -2.02% 3,774,397
04/03/26 1,003.57 $ -0.41% 1,965,539
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,001.35USD
Average target price
1,214.34USD
Spread / Average Target
+21.27%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW